Autolus Therapeutics
AUTL
69 hedge funds and large institutions have $170M invested in Autolus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 17 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
31% more capital invested
Capital invested by funds: $129M → $170M (+$40.2M)
10% more funds holding
Funds holding: 63 → 69 (+6)
4.29% more ownership
Funds ownership: 33.82% → 38.11% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$16.9M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$14.2M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$11.1M |
| 4 |
Goldman Sachs
New York
|
+$3.97M |
| 5 |
SCM
Sio Capital Management
New York
|
+$3.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$13M |
| 2 |
DM
Deerfield Management
New York
|
-$12.3M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$12.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$2.65M |
| 5 |
BlackRock
New York
|
-$1.51M |
AUTL Hedge Fund Activity: Q2 2021 in Review
69 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2021, worth a combined $170M — up 31% from $129M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AUTL positions and 17 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Capital International Investors, exiting entirely with an estimated $13M sold.
- 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2021, up from 63 in Q1 2021.
- Funds reported $170M of Autolus Therapeutics stock for Q2 2021, up 31% quarter-over-quarter.
- 23 funds opened new Autolus Therapeutics positions in Q2 2021 and 17 closed out, a net change of +6 holders.
- The largest Autolus Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $16.9M added.
- The largest Autolus Therapeutics seller in Q2 2021 was Capital International Investors, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2021.